Close Menu

NEW YORK – Molecular testing firm Invitae said on Thursday that it has begun enrolling prostate cancer patients in a study to improve understanding of how current germline genetic testing guidelines facilitate identification of variants that can impact their care.

Invitae's nationwide study will enroll men diagnosed with prostate cancer who meet current genetic testing guidelines and those who don't. Researchers will track patients to gauge whether access to genetic information changes their treatment and care recommendations, and assess their experience with testing. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.